KMT2A and leukemia: SNDX-5613 (Fig. 3) [119] has entered a phase 1/2 trial for the treatment of relapsed/refractory leukemias, including those harboring MLL1-r or nucleophosmin 1 (NPM1) mutation (NCT04065399, https://clinicaltrials.gov/).